MedPath
FDA Approval

Amikacin Sulfate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
November 17, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Amikacin(1 g in 4 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Emcure Pharmaceuticals Limited

916921919

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Emcure Pharmaceuticals Limited

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

Emcure Pharmaceuticals Limited

675467924

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Amikacin Sulfate

Product Details

NDC Product Code
23155-786
Application Number
ANDA204040
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
November 17, 2022
AmikacinActive
Code: N6M33094FDClass: ACTIMQuantity: 1 g in 4 mL
SODIUM METABISULFITEInactive
Code: 4VON5FNS3CClass: IACT
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
SODIUM CITRATEInactive
Code: 1Q73Q2JULRClass: IACT

Amikacin Sulfate

Product Details

NDC Product Code
23155-785
Application Number
ANDA204040
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
November 17, 2022
SODIUM METABISULFITEInactive
Code: 4VON5FNS3CClass: IACT
AmikacinActive
Code: N6M33094FDClass: ACTIMQuantity: 500 mg in 2 mL
SODIUM CITRATEInactive
Code: 1Q73Q2JULRClass: IACT
SULFURIC ACIDInactive
Code: O40UQP6WCFClass: IACT
© Copyright 2025. All Rights Reserved by MedPath